ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,942.47
1.26%
Dow Jones
42,732.13
0.80%
US Dollar vs MXN
20.6314
0.00%
Brent Oil
76.495
0.00%
Bitcoin
97,798.11
-0.42%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. aTyr Pharma Inc (ATYR)

  7. aTyr Pharma Inc (ATYR) Noticias

ATYR

aTyr Pharma (ATYR)

aTyr Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ATYR
FechaHoraFuenteTítuloSímboloCompañía
23/12/202415:48Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATYRaTyr Pharma Inc
23/12/202415:42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATYRaTyr Pharma Inc
17/12/202407:00GlobeNewswire Inc.aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ATYRaTyr Pharma Inc
12/12/202415:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATYRaTyr Pharma Inc
12/12/202415:12Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ATYRaTyr Pharma Inc
12/12/202415:00GlobeNewswire Inc.aTyr Pharma Announces the Appointment of Eric Benevich to its Board of DirectorsNASDAQ:ATYRaTyr Pharma Inc
10/12/202407:00GlobeNewswire Inc.aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary SarcoidosisNASDAQ:ATYRaTyr Pharma Inc
09/12/202407:00GlobeNewswire Inc.aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on FibrosisNASDAQ:ATYRaTyr Pharma Inc
15/11/202407:00GlobeNewswire Inc.aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on FibrosisNASDAQ:ATYRaTyr Pharma Inc
14/11/202417:51Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ATYRaTyr Pharma Inc
07/11/202415:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATYRaTyr Pharma Inc
07/11/202415:01GlobeNewswire Inc.aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate UpdateNASDAQ:ATYRaTyr Pharma Inc
31/10/202407:00GlobeNewswire Inc.aTyr Pharma to Present at Upcoming Investor ConferencesNASDAQ:ATYRaTyr Pharma Inc
15/10/202416:01Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ATYRaTyr Pharma Inc
08/10/202407:00GlobeNewswire Inc.aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual MeetingNASDAQ:ATYRaTyr Pharma Inc
02/10/202407:00GlobeNewswire Inc.aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory JournalNASDAQ:ATYRaTyr Pharma Inc
21/08/202407:00GlobeNewswire Inc.aTyr Pharma to Participate in September Investor ConferencesNASDAQ:ATYRaTyr Pharma Inc
13/08/202415:00GlobeNewswire Inc.aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update NASDAQ:ATYRaTyr Pharma Inc
06/08/202407:00GlobeNewswire Inc.aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical OperationsNASDAQ:ATYRaTyr Pharma Inc
30/07/202407:00GlobeNewswire Inc.aTyr Pharma Announces Research Study with Stanford MedicineNASDAQ:ATYRaTyr Pharma Inc
22/07/202407:00GlobeNewswire Inc.aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary SarcoidosisNASDAQ:ATYRaTyr Pharma Inc
03/06/202407:00GlobeNewswire Inc.aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”NASDAQ:ATYRaTyr Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:ATYR

Su Consulta Reciente

TG
A19VV4
Cooperatieve Rabobank UA
KUCN
KSMUSDT
Kusama
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados